Marisa Wexler, MS, senior science writer —

An international team led by scientists at the University of Toronto identified hundreds of proteins, from among nearly 10,000 screened, that interact with the CFTR protein in mammalian cells. These interacting proteins may be useful therapeutic targets for cystic fibrosis (CF), which is caused by mutations…

A team of scientists in New York has created small molecules called antisense oligonucleotides that could be used to “skip over” the mutated part of the CFTR gene to treat cystic fibrosis (CF) patients with a specific “nonsense” mutation and no available therapies. Findings were published in the study, “…

People with cystic fibrosis (CF) can have a complicated relationship with food and eating that changes over their lifetime, a series of patient interviews regarding diet reveals. For many patients, bad childhood experiences — needing feeding tubes and having to pack on more weight — impacted their perceptions of…

First Wave BioPharma has filed two new patents related to adrulipase, a yeast-derived enzyme that the company is developing to treat exocrine pancreatic insufficiency in people with cystic fibrosis (CF). One application is related to dosage forms, methods of treatment, and manufacturing methods for the investigational medication. This includes a…

The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of ACG-701, an investigational antibiotic to treat pulmonary exacerbations in people with cystic fibrosis (CF). “We appreciate the generous support of the Cystic Fibrosis Foundation and are looking forward to…

The European Commission has expanded its approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat children with cystic fibrosis (CF) as young as 6 who have the most common type of CF-causing mutation. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. approved a similar expansion.

Researchers at The Rockefeller University in New York City have determined how two medications used to treat cystic fibrosis (CF), lumacaftor and tezacaftor, interact with the CFTR protein. The results suggest that these medicines bind to the protein — usually impaired or missing in people with CF — and…

The Cystic Fibrosis Foundation has announced an investment in SalioGen Therapeutics to support the company’s preclinical research toward  developing a new gene therapy for cystic fibrosis (CF). SalioGen is working to advance a novel type of gene therapy, called Gene Coding, which is accomplished using the company’s…

EnBiotix has raised $11 million in financing that will help fund clinical testing of ColiFin (inhaled colistimethate sodium) and murepavadin, two antibiotics that may be useful for controlling lung infections in people with cystic fibrosis (CF). Some of the funding was from the Cystic Fibrosis Foundation,…

An endoscopic sinus surgery (ESS) is best performed within a few years of a lung transplant in cystic fibrosis (CF) patients, as longer wait times are associated with worse lung function and more antibiotic use, a small study reported. This finding could be relevant because “lung transplant recipients with CF…